Evidence map›Paper›PMID 31006772›Full record

Observational studyRevista espanola de salud publica2019

[Methodology of the 2nd seroprevalence study in Spain].

Aurora Limia Sánchez, María Vicenta Labrador Cañadas, Fernando de Ory Manchón, Laura Sánchez-Cambronero Cejudo, Iria Rodríguez Cobo, Elena Cantero Gudino, Julio Vázquez Moreno, Araceli Arce Arnáez

Abstract readObservational Study
In one paragraph

Observational study in Revista espanola de salud publica, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. [Seroprevalence of antibodies against measles virus in Galicia: trends during the last ten years depending on age and sex].Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2020
    Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Aurora Limia SánchezSubdirección General de Promoción de la Salud y Vigilancia en Salud Pública. Dirección General de Salud Pública, Calidad e Innovación. Ministerio de Sanidad, Consumo y Bienestar Social. Madrid. España.
María Vicenta Labrador CañadasSubdirección General de Promoción de la Salud y Vigilancia en Salud Pública. Dirección General de Salud Pública, Calidad e Innovación. Ministerio de Sanidad, Consumo y Bienestar Social. Madrid. España.
Fernando de Ory ManchónCentro Nacional de Microbiología. Madrid. España.
Laura Sánchez-Cambronero CejudoSubdirección General de Promoción de la Salud y Vigilancia en Salud Pública. Dirección General de Salud Pública, Calidad e Innovación. Ministerio de Sanidad, Consumo y Bienestar Social. Madrid. España.
Iria Rodríguez CoboSubdirección General de Promoción de la Salud y Vigilancia en Salud Pública. Dirección General de Salud Pública, Calidad e Innovación. Ministerio de Sanidad, Consumo y Bienestar Social. Madrid. España.
Elena Cantero GudinoSubdirección General de Promoción de la Salud y Vigilancia en Salud Pública. Dirección General de Salud Pública, Calidad e Innovación. Ministerio de Sanidad, Consumo y Bienestar Social. Madrid. España.
Julio Vázquez MorenoSubdirección General de Promoción de la Salud y Vigilancia en Salud Pública. Dirección General de Salud Pública, Calidad e Innovación. Ministerio de Sanidad, Consumo y Bienestar Social. Madrid. España.
Araceli Arce ArnáezSubdirección General de Promoción de la Salud y Vigilancia en Salud Pública. Dirección General de Salud Pública, Calidad e Innovación. Ministerio de Sanidad, Consumo y Bienestar Social. Madrid. España.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Seroprevalence studies are designed in population samples to assess the level and distribution of immunity induced by natural infection of certain infectious agents or by immunization against them. The purpose of the 2nd Seroprevalence Study in Spain is to assess the prevalence and distribution of immune status against vaccine-preventable diseases and generated by natural infection by other microorganisms. Pathologies specifically included in the study are: poliomyelitis, diphtheria, tetanus, pertussis, measles, rubella, mumps, varicella, invasive meningococcal disease by serogroup C, hepatitis A, hepatitis B, hepatitis E, hepatitis C and HIV. The study has a similar design of that conducted in 1996, as it is a descriptive cross-sectional study in resident population of 2 to 80 years of age in Spain. Two-stage conglomerate sampling was carried out on the population aged 2 to 80 years living in Spain, with an initial sample size of 10,000 people. The methodology of the study is described in this article.

Indexed as

AdolescentAdultAgedAged, 80 and overBacterial InfectionsChildChild, PreschoolCross-Sectional StudiesFemaleHumansImmunity, HumoralImmunogenicity, VaccineMaleMiddle AgedResearch DesignSeroepidemiologic StudiesCross-sectional surveyImmunization programInfectious diseasesMethodologyProgram evaluationSeroepidemiological studySeroprevalenceSpainVaccinationVaccine-preventable diseases

Identifiers

PMID31006772
PMCPMC10560962

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.